Polar Capital launches biotechnology Ucits
Polar Capital has launched a biotechnology Ucits, which will be managed by David Pinniger.
Pinniger joined Polar in August this year from SV Life Sciences, where he was manager of the International Biotechnology Trust for five years.
The new Ucits will be an open ended fund, focused on investing in a globally diversified portfolio of biotechnology companies, seeking to achieve long term capital growth.
The portfolio will consist of between 40-60 stocks, and will be benchmarked against the Nasdaq Biotechnology index.
Pinniger said: “We believe the global biotechnology industry is poised to deliver significant value creation over the coming years driven by a major new innovation cycle. It is our view that the sector’s stock market resurgence in recent years could be just the start of a multi-year re-rating as this high growth global industry comes of age.”
“Advances in information technology – in particular increases in computer processing power – are enabling medical science to make rapid advances in understanding the complex biology of health and disease. In recent years we’ve also seen a proliferation of tools and technologies that are enabling new ways of targeting the molecular basis of disease.”
“The era of personalised medicine is now upon us. The ability of healthcare professionals to deliver the right treatment, to the right patient, at the right time is helping to transform the effectiveness of healthcare delivery throughout the world. The highly innovative products being developed by biotechnology companies are playing a central role in this exciting new era.”